Diazepam (Valium) Is Not Recommended for Migraine Treatment
Diazepam has no established role in the treatment or prevention of migraine headaches and is not supported by current evidence-based guidelines. The FDA-approved indications for Valium include anxiety disorders, acute alcohol withdrawal, skeletal muscle spasm, and adjunctive use in convulsive disorders—but notably, migraine is not among these indications 1.
Why Clinicians Might Consider It (But Shouldn't)
Historical Context and Misuse
Some older studies explored benzodiazepines in migraine contexts, but the evidence is weak or contradictory:
Detoxification protocols: One study used diazepam combined with methylprednisolone as a bridge therapy for medication overuse headache (MOH), showing some benefit in the withdrawal phase 2. However, this represents treatment of a complication (MOH), not migraine itself.
Comparative studies showed no benefit: A 1982 double-blind trial comparing chlormezanone, diazepam, and placebo for acute migraine attacks found no significant effect of diazepam over placebo 3. Another study comparing IV dihydroergotamine versus IV diazepam for intractable migraine showed diazepam was markedly inferior—only 7 of 54 patients became headache-free with diazepam (versus 49 of 55 with DHE) 4.
Vestibular migraine: Diazepam has been mentioned for basilar migraine with vestibular symptoms 5, but this represents a highly specific subtype and is not generalizable to typical migraine.
Theoretical Mechanisms (That Don't Translate to Clinical Benefit)
Benzodiazepines like diazepam work through GABA-A receptor modulation, providing anxiolytic, muscle relaxant, and sedative effects. While muscle tension and anxiety can accompany migraines, treating these symptoms with benzodiazepines does not address the underlying neurovascular pathophysiology of migraine.
Evidence-Based Treatment Instead
Current guidelines are clear and consistent 6, 7, 8, 9:
For Acute Migraine Treatment:
- First-line: NSAIDs (aspirin, ibuprofen, naproxen sodium) or combination acetaminophen/aspirin/caffeine
- Second-line: Triptans (sumatriptan, rizatriptan, zolmitriptan, naratriptan)
- Adjunctive: Antiemetics (metoclopramide, domperidone) for nausea
For Migraine Prevention:
First-line agents include propranolol (80-240 mg/d), timolol (20-30 mg/d), amitriptyline (30-150 mg/d), divalproex sodium (500-1500 mg/d), or sodium valproate (800-1500 mg/d) 6.
Critical Safety Concern
A 2017 population-based study found that short-acting benzodiazepine use was associated with increased migraine occurrence (adjusted OR = 1.69,95% CI = 1.59-1.80) 10. This suggests benzodiazepines may actually worsen migraine frequency rather than help.
Common Pitfalls to Avoid
- Do not use benzodiazepines as migraine abortive therapy—they lack efficacy and carry risks of dependence, sedation, and potentially increased headache frequency
- Avoid opioids and barbiturates for similar reasons—questionable efficacy, high adverse event profile, and dependency risk 7, 6, 9
- Limit acute medication use to no more than 10 days per month to prevent medication overuse headache 9
If a patient presents using diazepam for migraine, transition them to evidence-based therapies using stratified care: NSAIDs for mild-to-moderate attacks, triptans for moderate-to-severe attacks, and consider preventive therapy if attacks occur ≥2 times per month with significant disability 6, 7, 9.